Abstract
Prostate-Specific antigen (PSA) is one of the most popular biomarkers for prostate carcinoma (PCA) at present. PSA indicates initial cancer and recurrence following therapy, but does not distinguish clearly from local or remote lesions. Molecular and functional scans, which can give a thorough and complete picture of PCR amplification, are a more robust instrument for detecting and assessing the progression of cancer at the stage as well as at subsequent stages. In this paper, PET or CT, MRI are useful for diagnosing, staging and regrading of PCA, as well as their application to prognostic, therapeutic and therapeutic evaluation. Novel imaging techniques, including novel radiotracers and PET/MRI, are also presented in this paper. Looking forward, the evolution of imaging techniques holds promise for improved PCA management. Continued innovation in radiotracers and hybrid imaging technologies such as PET/MRI could revolutionize early detection, accurate staging, and effective treatment, paving the way for precision oncology in prostate cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
